Triplet Therapy Slows Refractory Multiple Myeloma
Progression-free survival longer with once-weekly selinexor-containing regimen versus standard bortezomib and dexamethasone
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.